Franklin Biotechnology has experienced managers, but limited supporting resources and a sensible yet undistinguished process limit its appeal.
Franklin Biotechnology Discovery Fund Class A FBDIX
- NAV / 1-Day Return 167.83 / −2.10 %
- Total Assets 1.0B
-
Adj. Expense Ratio
1.020%
- Expense Ratio 1.010%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 1.81%
- Turnover 22%
USD | NAV as of Jun 11, 2026 | 1-Day Return as of Jun 11, 2026, 12:11 AM GMT+0
Morningstar’s Analysis FBDIX
Will FBDIX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
The People Pillar is our evaluation of the FBDIX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.
Parent Pillar
The Parent Pillar is our rating of FBDIX’s parent organization’s priorities and whether they’re in line with investors’ interests.
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 37.8
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Jazz Pharmaceuticals PLC | 5.53 | 57M | Healthcare |
Amgen Inc | 4.73 | 49M | Healthcare |
Gilead Sciences Inc | 4.65 | 48M | Healthcare |
Regeneron Pharmaceuticals Inc | 4.15 | 43M | Healthcare |
Vertex Pharmaceuticals Inc | 4.01 | 42M | Healthcare |
argenx SE ADR | 3.69 | 38M | Healthcare |
Ascendis Pharma AS | 2.87 | 30M | Healthcare |
Insmed Inc | 2.81 | 29M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 2.81 | 29M | Healthcare |
Franklin Instl U.S. Govt Mny Mkt Fund | 2.51 | 26M | Cash and Equivalents |
United States